{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-10-22",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "discontinued_date": "07/23/2026",
      "update_type": "New",
      "initial_posting_date": "07/23/2026",
      "package_ndc": "63459-390-08",
      "generic_name": "Bendamustine Hydrochloride Injection, Solution",
      "contact_info": "(610) 344-0200",
      "related_info": "A business decision has been made to discontinue manufacture of the drug.",
      "update_date": "07/23/2026",
      "therapeutic_category": [
        "Oncology"
      ],
      "dosage_form": "Injection",
      "presentation": "Treanda, Injection, Solution, 25 mg/5 mL, 1 vial, Single-Dose in 1 carton (NDC 63459-390-08)",
      "company_name": "Cephalon, LLC (a wholly owned subsidiary of Teva Pharmaceutical Industries, Ltd.)",
      "status": "To Be Discontinued"
    }
  ]
}